Starting at higher body weight If you are beginning your GLP-1 protocol at a higher body weight, you likely have ample subcutaneous tissue at all three injection sites
Caution notes If you have high blood pressure, kidney disease, heart disease, or have been told to limit sodium or potassium, talk to your healthcare provider before using electrolyte supplements regularly
Despite all the changes, it seems likely that compounding pharmacies will continue to offer GLP-1 drugs, at least for the foreseeable future, says Brunner: Some patients will be able to maintain these therapies at a price point they can afford in a customized formulation. The Takeaway The FDA ordered compounding pharmacies to stop producing and selling copies of GLP-1 injectable drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, as official shortages have ended
Circulating INSL-5 levels are estimated to be in the picomolar range (164, 172), which is several orders of magnitude lower than the EC 50 of INSL-5 on RXRP4 (166) and the supraphysiological concentrations used in the majority of insulin secretion experiments may have contributed to the conflicting results
We vet everything on PubMed so you dont have to